Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727505 | 0.95 | SMN1; SMN2 (0.41) | SMN1; SMN2KIF11KDM4ETAAR1SMYD2 | |
| SCHEMBL30426193 | 0.90 | SMN1; SMN2 (0.40) | SMN1; SMN2KIF11KDM4ETAAR1SMYD2 | |
| SCHEMBL15679439 | 0.90 | SMN1; SMN2 (0.40) | SMN1; SMN2KIF11KDM4ETAAR1SMYD2 | |
| SCHEMBL29026181 | 0.90 | SMN1; SMN2 (0.40) | SMN1; SMN2KIF11KDM4ETAAR1SMYD2 | |
| SCHEMBL927307 | 0.90 | SMN1; SMN2 (0.40) | SMN1; SMN2KIF11KDM4ETAAR1SMYD2 | |
| SCHEMBL2818126 | 0.89 | SMN1; SMN2 (0.38) | SMN1; SMN2KIF11TAAR1SMYD2CYP3A4 | |
| SCHEMBL3933299 | 0.88 | SMN1; SMN2 (0.37) | SMN1; SMN2SMYD2CYP3A4HTT | |
| SCHEMBL31400145 | 0.86 | SMN1; SMN2 (0.37) | SMN1; SMN2SMYD2CYP3A4HTT | |
| SCHEMBL15645028 | 0.86 | SMN1; SMN2 (0.37) | SMN1; SMN2SMYD2CYP3A4HTT | |
| SCHEMBL3939837 | 0.86 | SMN1; SMN2 (0.37) | SMN1; SMN2SMYD2CYP3A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125383-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025098391-A9 | SELECTIVE DRUG RELEASE FROM CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | NONA BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2026-04-30 | — | — | WO | disclosed |
| US-20260115139-A1 | Amino Acid-Containing Ionizable Lipids for the Delivery of Therapeutic Agents | NANOVATION THERAPEUTICS INC. (CA) | 2026-04-30 | — | — | US | disclosed |
| EP-4694981-A1 | HETEROCYCLIC COMPOUNDS AS DUAL INHIBITORS OF PD-L1 AND ADENOSINE RECEPTORS | Aurigene Oncology Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025202022-A9 | ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025202022-A1 | ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 | BAYER AKTIENGESELLSCHAFT (DE) | 2025-10-02 | — | — | WO | disclosed |
| EP-4594293-A1 | AMINO ACID-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF THERAPEUTIC AGENTS | Nanovation Therapeutics Inc. (CA) | 2025-08-06 | — | — | EP | disclosed |
| US-20250235547-A1 | ANTIBODY-DRUG CONJUGATE | UBE CORPORATION (JP) | 2025-07-24 | — | — | US | disclosed |
| WO-2025151594-A1 | FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20250170267-A1 | ANTIBODY-DRUG CONJUGATE PRECURSOR AND INTERMEDIATE FOR SYNTHESIS THEREOF | UBE CORPORATION (JP) | 2025-05-29 | — | — | US | disclosed |
| US-6355257-B1 | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-03-12 | — | — | US | disclosed |
| US-6303347-B1 | VACCINES | CORIXA CORPORATION | 2001-10-16 | — | — | US | disclosed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001034617-A2 | AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| US-6113918-A | IMMUNOLOGY | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
| EP-0983286-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050399-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0104888-B1 | PROCESS FOR PREPARING 2-HYDROXY-2-PHENYLETHYLAMINES | ELI LILLY AND COMPANY (US) | 1986-10-15 | — | — | EP | disclosed |
| EP-0104888-A1 | Process for preparing 2-hydroxy-2-phenylethylamines | ELI LILLY AND COMPANY (US) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115139-A1 | Amino Acid-Containing Ionizable Lipids for the Delivery of Therapeutic Agents | SLC43A1, SLC7A1, SLC7A5 | SMN1; SMN2 667/4885KIF11 3050/4885KDM4E 4032/4885 |
| US-20260125383-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | CGAS, PRKG1, GMPS | SMN1; SMN2 3863/4885KIF11 4672/4885KDM4E 4755/4885 |
| US-20250235547-A1 | ANTIBODY-DRUG CONJUGATE | LDHB, LDHA, DLST | SMN1; SMN2 3309/4885KIF11 616/4885KDM4E 2501/4885 |
| US-20250170267-A1 | ANTIBODY-DRUG CONJUGATE PRECURSOR AND INTERMEDIATE FOR SYNTHESIS THEREOF | DLST, LANCL1, DDOST | SMN1; SMN2 2577/4885KIF11 1209/4885KDM4E 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.